Abstract
Lipoprotein-associated Phospholipase A2 (Lp-PLA2) is an enzyme that belongs to the A2 Phospholipase superfamily and is produced by inflammatory cells that are involved in the process of atherogenesis. Even though there is controversy in current bibliography whether Lp-PLA2 exerts proatherogenic or anti-atherogenic properties, the weight of evidence suggests a pro-atherogenic role for this protein. Lp-PLA2 is detected in human atherosclerotic lesions and elevated Lp-PLA2 levels are associated with an increased risk of cardiovascular events and adverse events in patients with coronary artery disease independently of traditional risk factors and other markers of inflammation. It has been recently shown that direct pharmacological inhibition of Lp-PLA2 activity exerts beneficiary effects on the atherosclerotic process. This finding is most interesting since it could offer a novel target for therapeutic intervention in patients suffering from cardiovascular disease. The purpose of this review article is to report on the role of Lp-PLA2 in cardiovascular diseases and to enlighten the putative pathophysiologic mechanisms by which this protein exerts its effect on cardiovascular function. Additionally, the pharmacological interventions that influence Lp-PLA2 activity and may offer a new approach for the treatment of atherosclerosis will be analyzed.
Keywords: Lp-PLA2, PAF-AH, inflammatory biomarkers, cardiovascular disease
Reviews on Recent Clinical Trials
Title: The Role of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in Cardiovascular Disease
Volume: 6 Issue: 2
Author(s): Ignatios Ikonomidis, Christos A. Michalakeas, John Lekakis, John Parissis and Maria Anastasiou-Nana
Affiliation:
Keywords: Lp-PLA2, PAF-AH, inflammatory biomarkers, cardiovascular disease
Abstract: Lipoprotein-associated Phospholipase A2 (Lp-PLA2) is an enzyme that belongs to the A2 Phospholipase superfamily and is produced by inflammatory cells that are involved in the process of atherogenesis. Even though there is controversy in current bibliography whether Lp-PLA2 exerts proatherogenic or anti-atherogenic properties, the weight of evidence suggests a pro-atherogenic role for this protein. Lp-PLA2 is detected in human atherosclerotic lesions and elevated Lp-PLA2 levels are associated with an increased risk of cardiovascular events and adverse events in patients with coronary artery disease independently of traditional risk factors and other markers of inflammation. It has been recently shown that direct pharmacological inhibition of Lp-PLA2 activity exerts beneficiary effects on the atherosclerotic process. This finding is most interesting since it could offer a novel target for therapeutic intervention in patients suffering from cardiovascular disease. The purpose of this review article is to report on the role of Lp-PLA2 in cardiovascular diseases and to enlighten the putative pathophysiologic mechanisms by which this protein exerts its effect on cardiovascular function. Additionally, the pharmacological interventions that influence Lp-PLA2 activity and may offer a new approach for the treatment of atherosclerosis will be analyzed.
Export Options
About this article
Cite this article as:
Ikonomidis Ignatios, A. Michalakeas Christos, Lekakis John, Parissis John and Anastasiou-Nana Maria, The Role of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in Cardiovascular Disease, Reviews on Recent Clinical Trials 2011; 6 (2) . https://dx.doi.org/10.2174/157488711795177903
DOI https://dx.doi.org/10.2174/157488711795177903 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurocognitive Monitoring and Care During Pediatric Cardiopulmonary Bypass — Current and Future Directions
Current Cardiology Reviews Glucose Lowering Activity of the Aqueous Extract of Warionia saharae in Normal and Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Prodrug Designing of NSAIDs
Mini-Reviews in Medicinal Chemistry The Role of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease Diagnosis. Where are we Now?
Recent Patents on CNS Drug Discovery (Discontinued) Astrocytes and Inflammasome: A Possible Crosstalk in Neurological Diseases
Current Medicinal Chemistry An Update on GABA Analogs for CNS Drug Discovery
Recent Patents on CNS Drug Discovery (Discontinued) Glomerular Endothelium and its Impact on Glomerular Filtration Barrier in Diabetes: Are the Gaps Still Illusive?
Current Medicinal Chemistry Nutritional Deficiency in Early Life Facilitates Aging-Associated Cognitive Decline
Current Alzheimer Research Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications
Current Vascular Pharmacology The Development of New Low-Molecular-Weight Factor Xa Inhibitors that are Potential Anticoagulants
Current Drug Discovery Technologies A Comprehensive Review on Exosomes and Microvesicles as Epigenetic Factors
Current Stem Cell Research & Therapy Tetramethylpyrazine Attenuates Oxygen-glucose Deprivation-induced Neuronal Damage through Inhibition of the HIF-1α/BNIP3 Pathway: from Network Pharmacological Finding to Experimental Validation
Current Pharmaceutical Design The Renin Inhibitor Aliskiren as Novel Treatment for Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Genetic and Non-Genetic Determinants of the Pharmacological Activity of Statins
Current Drug Metabolism Cellular Mechanisms of the Protective Effect of Polyphenols on the Neurovascular Unit in Strokes
Cardiovascular & Hematological Agents in Medicinal Chemistry The Importance of Alkynyl Chain Presence for the Activity of Adenine Nucleosides/Nucleotides on Purinergic Receptors
Current Medicinal Chemistry Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry Vulnerable Plaque Versus Vulnerable Patient: Emerging Blood Biomarkers for Risk Stratification
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Findings Confirm LIM Domain Kinases as Emerging Target Candidates for Cancer Therapy
Current Cancer Drug Targets Prognostic Significance of Homocysteine Levels in Acute Ischemic Stroke: A Prospective Cohort Study
Current Neurovascular Research